19-Year-Old Wins $100,000 for Corn Husk Drug Breakthrough
Slovakian Teen Seizes $100,000 After Revolutionizing Antiviral Drug
When 19‑year‑old Adam Kovalčík flew to Ohio for the Regeneron International Science and Engineering Fair (ISEF), he didn’t anticipate returning home with a five‑figure prize.
The Game‑Changing Compound: Galidesivir
Galidesivir is a cutting‑edge antiviral that targets RNA viruses—COVID‑19, Ebola, and Zika. Early studies show it can neutralize these pathogens, yet its full clinical profile remains incomplete.
Cost‑Cutting Breakthrough
- Adam’s method reduces production cost from $75 per gram to about $12.50.
- It replaces the current 15‑step manufacturing process with just 10 steps.
- By using corn waste as a raw material, he doubled the drug’s yield.
Beyond Galidesivir
Adam also applied his technique to create a new antiviral, opening doors for broader RNA‑virus therapy.
Recognition at ISEF
The judging panel, chaired by retired chemist Chris RoDee, awarded Adam the $100,000 George D. Yancopoulos Innovator Award.
“I cannot describe this feeling,” Adam said after the ceremony. “I did not expect such a huge international competition to be won by someone from a small village in a small European country, so it was just pure shock.”
Business Insider Presents Pioneering Scientific Narratives
Accelerated Pathway to Galidesivir Discovery
RoDee remarked on a streamlined approach that effectively transformed a traditionally protracted process into a half‑step progression. His unconventional entry point reduced the sequence from three to merely one step, offering a decisive advantage.
Kovalčík’s Achievements and Progress Timeline
- The routine manufacturing schedule requires nine days, while Kovalčík’s experimental method concludes in five days.
- A secondary compound was subsequently produced, demonstrating Kovalčík’s capacity to diversify therapeutic outputs.
Efficacy Forecast for Novel Molecule
Preliminary computational estimations propose that Kovalčík’s recently synthesized molecule could exhibit a potency up to five times greater than galidesivir in a COVID‑19 context. The stronger binding affinity to viral enzymes is anticipated to enhance viral eradication.
Key Takeaway
Both scientists illustrate the transformative potential of strategic process optimization, underscoring the importance of innovative thinking in drug development.
Big plans for drugs and perfume
Kovalčík’s Patent and Partnership with Slovak Research
Dr. Kovalčík has filed a preliminary patent covering his new method for synthesising the antiviral galidesivir. The invention will need to be scaled up before it can be sold commercially, but the scientist has already secured support from a team at the Slovak University of Technology in Bratislava.
Scaling Up Galactic Production
- At present the process can yield about 200 litres of galidesivir, a figure that the researcher thinks is acceptable for laboratory testing but far too low for a clinical trial.
- Kovalčík is working with the university’s chemists to devise a technique that will allow the projectile to produce multiple thousands of litres of the medicine.
- He is also exploring how the same methodology could be applied to other drug-synthesis processes, a cross‑disciplinary endeavour that could attract further funding.
Expanding the Research Landscape
“The university has a wealth of design strategies and limitless new drugs ready for creation and testing,” Kovalčík says. It is a partnership that will be mutually beneficial and a strong foundation for future breakthroughs.
Beyond Antivirals: Eco‑Friendly Perfume Company
Kovalčík’s vision is not limited to pharmaceuticals. He has announced a plan to harness his chemistry expertise, coupled with the prize money he earned at the competition, to launch a company that manufactures eco‑friendly perfumes from corn.
“On the very first day I entered a laboratory, I knew that my passion would revolve around chemistry,” he says. “Now that I have been recognized for it, I feel incredible.”
